ReviewInternational journal of medical sciences2011
Current status of methods to assess cancer drug resistance.
Review in International journal of medical sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 73 citations in OpenAlex.
- Review
- Empowering the Battle: Bioenhancers as Allies Against Cancer Drug Resistance.Current pharmaceutical biotechnology · 2024Review
- Cancer Chemoresistance; Recent Challenges and Future Considerations.Cancer treatment and research · 2023Article
- Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells.Pharmaceutics · 2022Review
- Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors.Cancers · 2022Review
- Capillary microsampling-based single-cell metabolomics by mass spectrometry and its applications in medicine and drug discovery.Cancer biomarkers : section A of Disease markers · 2022Article
- Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them.International journal of molecular sciences · 2021Review
- Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells.Aging · 2021Article
- Penile Cancer-Derived Cells Molecularly Characterized as Models to Guide Targeted Therapies.Cells · 2021Article
- Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.International journal of molecular sciences · 2020Review
- Towards early monitoring of chemotherapy-induced drug resistance based on single cell metabolomics: Combining single-probe mass spectrometry with machine learning.Analytica chimica acta · 2019Article
- Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.Cancer chemotherapy and pharmacology · 2019Article
- Review
- Towards rapid prediction of drug-resistant cancer cell phenotypes: single cell mass spectrometry combined with machine learning.Chemical communications (Cambridge, England) · 2019Article
- Chemotherapy Resistance in Advanced Ovarian Cancer Patients.Biomarkers in cancer · 2019Review
- Disruption of mitochondrial homeostasis with artemisinin unravels anti-angiogenesis effects via auto-paracrine mechanisms.Theranostics · 2019Article
- Distinctive behaviour of live biopsy-derived carcinoma cells unveiled using coherence-controlled holographic microscopy.PloS one · 2017Article
- Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.Oncotarget · 2015Review
- EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.Integrative biology : quantitative biosciences from nano to macro · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance is the main cause of the failure of chemotherapy of malignant tumors, resistance being either preexisting (intrinsic resistance) or induced by the drugs (acquired resistance). At present, resistance is usually diagnosed during treatment after a long period of drug administration.In the present paper, methods for a rapid assessment of drug resistance are described. Three main classes of test procedures can be found in the literature, i.e. fresh tumor cell culture tests, cancer biomarker tests and positron emission tomography (PET) tests. The methods are based on the evaluation of molecular processes, i.e. metabolic activities of cancer cells. Drug resistance can be diagnosed before treatment in-vitro with fresh tumor cell culture tests, and after a short time of treatment in-vivo with PET tests. Cancer biomarker tests, for which great potential has been predicted, are largely still in the development stage. Individual resistance surveillance with tests delivering rapid results signifies progress in cancer therapy management, by providing the possibility to avoid drug therapies that are ineffective and only harmful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.